A catastrophic vascular emergency, abdominal aortic aneurysm rupture accounts for substantial cardiovascular mortality worldwide. Traditionally, clinicians rely on aortic diameter thresholds and expansion velocity to gauge catastrophic failure risks. However, structural dimensions often fail to capture the complex, underlying biological instability of aneurysmal tissue. Consequently, patients with moderate arterial dilatation can experience sudden vascular collapse without warning. Emerging experimental data indicate that localized metabolic changes dictate vascular wall degradation and wall stress adaptation. Specifically, vascular cells shift from quiescent oxidative metabolism to high-flux glycolysis during tissue deterioration. Deciphering these metabolic switches provides an opportunity to identify novel biomarkers and preventive therapies.

Understanding Abdominal Aortic Aneurysm Rupture and Metabolic Divergence

Vascular biology studies demonstrate that tissue destruction stems from persistent cellular stress and structural destabilization. In modern vascular research, scientists evaluated intact and ruptured aneurysmal tissue using an established AngII/BAPN murine model. While both tissue states displayed severe immune infiltration and inflammation, standard transcriptomic signatures showed surprising similarities between intact and ruptured states. Therefore, inflammatory gene activation alone cannot explain terminal vessel wall disruption. Conversely, untargeted metabolomic profiling revealed profound metabolic divergence between stable aortic segments and ruptured walls. Ruptured tissue demonstrated extensive remodeling of critical energy pathways, marked nucleotide metabolism turnover, and altered cyclic nucleotide signaling cascades. Consequently, these data underscore that metabolic exhaustion and unconstrained energy shifts critically accelerate structural failure.

USP53 as a Master Deubiquitinase in Vascular Remodeling

To identify the molecular drivers of this metabolic shift, investigators integrated transcriptomic profiles with proteomic screening. Among diverse ubiquitin-specific proteases, ubiquitin-specific protease 53 emerged as a pivotal factor during disease progression. Expression levels of USP53 increased markedly during early aneurysm expansion and peaked during terminal rupture. Normally, deubiquitinating enzymes maintain cellular homeostasis by preventing proteasomal destruction of targeted substrate proteins. However, aberrant USP53 upregulation disrupts protein turnover networks within the vascular wall. Furthermore, elevated protease expression directly correlates with the disruption of arterial architecture. Thus, investigators identified USP53 as a previously unrecognized regulatory driver connecting post-translational protein modification to destructive aortic wall remodeling.

Glycolytic Shift in Vascular Smooth Muscle Cells

Human aortic smooth muscle cells preserve aortic tensile strength and maintain healthy extracellular matrix architecture. However, experimental overexpression of USP53 dramatically alters cellular energetics in these contractile cells. Specifically, USP53 upregulation increases glucose transporter translocation and triggers excessive cellular glucose consumption. Concurrently, smooth muscle cells accelerate lactate secretion and deplete intracellular energy reserves. This metabolic state mimics aerobic glycolysis, commonly observed in rapidly dividing, dedifferentiated cells. Moreover, elevated glycolytic flux suppresses vital oxidative phosphorylation pathways within the cellular mitochondria. Smooth muscle cells subsequently abandon their mature contractile duties, activate synthetic pathways, and release destructive proteases. Consequently, this metabolic reprogramming erodes vascular wall integrity, increasing biomechanical vulnerability under physiological systemic pressure.

Translational Insights from Experimental Silencing

Therapeutic validation studies have demonstrated the clinical promise of interrupting this destructive enzymatic cascade. Researchers deployed adeno-associated viral vectors to silence USP53 expression in aneurysmal murine models. Notably, USP53 knockdown attenuated outward arterial dilatation and preserved medial wall architecture. Silencing the deubiquitinase also prevented the catastrophic loss of elastic lamina layers and decreased smooth muscle cell apoptosis. Furthermore, targeted knockdown partially reversed metabolic derangements by lowering abnormal lactate accumulation and restoring mitochondrial function. Consequently, animals treated with vector-mediated gene silencing displayed significantly improved survival rates without spontaneous vascular collapse. Therefore, inhibiting excessive glycolytic turnover directly shields vulnerable vascular conduits from lethal biomechanical failure.

Clinical Implications for Cardiovascular Risk Stratification

These molecular discoveries carry meaningful implications for modern cardiovascular diagnostics and pharmacological design. Present guidelines emphasize watchful waiting until aortic diameters surpass surgical thresholds. Nevertheless, pharmacological options that arrest active tissue expansion remain practically nonexistent in outpatient practice. Molecular targeting of USP53 or downstream glycolytic pathways could provide a pharmacological bridge to prevent rupture in borderline cases. In addition, assessing metabolic alterations through advanced positron emission tomography or biochemical biomarkers may enhance diagnostic accuracy. Identifying patients who harbor intense vascular glycolysis could refine personalized risk assessments beyond conventional luminal measurements. Ultimately, halting metabolic reprogramming presents a viable strategy to preserve vascular resilience and prevent mortality.

Frequently Asked Questions

How does USP53 influence vascular smooth muscle cell metabolism in aneurysms?

USP53 functions as a critical deubiquitinase that accelerates glucose transporter expression and elevates glucose uptake within human aortic smooth muscle cells. Consequently, these cells generate excessive lactate, downregulate mitochondrial oxidative phosphorylation, and adopt a highly glycolytic phenotype. This metabolic switch promotes smooth muscle cell dedifferentiation, impairs cellular repair capabilities, and accelerates aortic matrix degradation.

Why is metabolic reprogramming significant in abdominal aortic aneurysm rupture?

While vascular inflammation initiates aneurysm formation, metabolic reprogramming distinguishes ruptured aneurysmal tissue from intact walls. When vascular smooth muscle cells switch to aerobic glycolysis, energy production becomes inefficient and metabolic stress increases. Consequently, this metabolic failure weakens connective tissue architecture, limits cellular structural defense, and drastically amplifies biomechanical susceptibility to arterial rupture under arterial pressures.

Can deubiquitinase inhibition become a targeted medical therapy for aneurysm stabilization?

Preclinical studies confirm that silencing USP53 via viral vector delivery normalizes local metabolic disturbances and halts aortic matrix destruction. Because no pharmacological agents currently prevent aneurysm expansion, developing small-molecule deubiquitinase inhibitors represents a compelling translational frontier. Such targeted therapies could stabilize vulnerable vascular walls and provide non-surgical options for high-risk cardiovascular patients.

Disclaimer: This content is for informational and educational purposes only and should not be construed as clinical guidance or medical advice. Refer to the latest local and national guidelines for clinical practice.

References

1. Chen Y et al. USP53 regulates glycolytic reprogramming and accelerates Abdominal aortic aneurysm progression and rupture. Nucleosides Nucleotides Nucleic Acids. 2026 Oct 03. doi: 10.1080/15257770.2026.2738805. PMID: 42827389.
2. Tsuruda T, et al. Inhibition of development of abdominal aortic aneurysm by glycolysis restriction. Arterioscler Thromb Vasc Biol. 2012;32(6):1410-1417.
3. Chaikof EL, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018;67(1):2-77.e2.
4. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis and vascular disease. Nat Rev Cardiol. 2012;9(6):310-323.